Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Objective To determine the effects of volanesorsen (ISIS 304801), a second-generation 2'-O-methoxyethyl chimeric antisense inhibitor of apolipoprotein (apo)C-III, on triglyceride (TG) levels and insulin resistance in patients with type 2 diabetes. Research design and methods A randomized, double-blind, placebo-controlled trial was performed in 15 adult patients with type 2 diabetes (HbA1c >7.5% [58 mmol/mol]) and hypertriglyceridemia (TG >200 and Results Treatment with volanesorsen significantly reduced plasma apoC-III (-88%, P = 0.02) and TG (-69%, P = 0.02) levels and raised HDL cholesterol (HDL-C) (42%, P = 0.03) compared with placebo. These changes were accompanied by a 57% improvement in whole-body insulin sensitivity (P Conclusions Volanesorsen reduced plasma apoC-III and TG while raising HDL-C levels. Importantly, glucose disposal, insulin sensitivity, and integrative markers of diabetes also improved in these patients after short-term treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The COMPASS trial, which evaluated volanesorsen in patients with multifactorial chylomicronemia (with partial LPL activity), similarly demonstrated substantial TG reductions (~ 71%) and improved metabolic parameters, broadening the potential utility of apoC-III inhibition beyond the rare FCS population.”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [47]
In the citing paper
“In addition to TG lowering, volanesorsen has been shown to reduce apoC-III by ~ 80–88% and increase HDL-C by ~ 42% compared with placebo [45–47].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [47]
In the citing paper
“This correlated with >80% reductions in apo C-III, favourable changes across multiple lipoprotein species, unchanged LDL-C and improved carbohydrate metabolism.69–71”
From Clinical review on triglycerides (2020) · cites this paper as [70]
In the citing paper
“In the liver, nicotinic acid inhibits diacylglycerol acyltransferase2 resulting in decreased secretion of VLDL particles, which is also reflected in reductions of plasma levels of both IDL and LDL particles [335].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [335]
In the citing paper
“Nicotinic acid primarily raises HDL-C and ApoA1 by stimulating ApoA1 production in the liver [335].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [335]
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Muniyappa, R., Lee, S., Chen, H., & Quon, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00645.2007 · Cited by 1,643
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919 · cited 1×
“Two recent Mendelian randomization studies showed that individuals with loss-of-function APOC3 variants had lower TG concentrations and LDL-C, higher HDL-C, and, compellingly, a 40% reduction in risk of coronary heart disease (15,16).”
BackgroundESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationWu, L., & Parhofer, K. G. (2014) · Metabolism · doi:10.1016/j.metabol.2014.08.010 · Cited by 516
Cited by
Items 101–171 of 171
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease
Tsimikas, S. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01345-4 · Cited by 16
Bi, C., Wang, L., Sun, C., Sun, M., Zheng, P., Xue, Z., Shen, L., Pan, P., Li, J., Lv, Y., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028652 · Cited by 15
Pek, S. L. T., Sum, C. F., Yeoh, L. Y., Lee, S. B. M., Tang, W. E., Lim, S. C., & Subramaniam, T. (2017) · Metabolism · doi:10.1016/j.metabol.2017.03.016 · Cited by 14
Masson, W., Lobo, M., Nogueira, J. P., Corral, P., Barbagelata, L., & Siniawski, D. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09893-x · Cited by 12
“One study exclusively enrolled patients with type 2 diabetes [10], while another focused solely on patients with familial partial lipodystrophy [13].”
Novel Therapeutics for Familial Chylomicronemia Syndrome
Izar, M. C. D. O., & Fonseca, F. A. H. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01295-x · Cited by 13
“Volanesorsen has also been evaluated in patients with type 2 diabetes mellitus (T2DM) (N = 15, 15-week phase 2 study) [37] and familial partial lipodystrophy (FPL) (N = 40, 13-week phase 2/3 study) [38], with respective TG reductions of 69% and 88%.”
The Future of Lipid-Lowering Therapy
Zwol, W. H.-V., Rimbert, A., & Kuivenhoven, J. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071085 · Cited by 14
“Volanesorsen has also been reported to improve insulin sensitivity and is anticipated to be of use in patients with type 2 diabetes [69].”
BackgroundDo Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01153-8 · Cited by 13
Cervantes, J., Koška, J., Kramer, F., Akilesh, S., Alpers, C. E., Mullick, A. E., Reaven, P. D., & Kanter, J. E. (2024) · JCI Insight · doi:10.1172/jci.insight.177268 · Cited by 15
“In addition to the reductions in TRLs, silencing APOC3 reduced blood glucose in a type 2 diabetes model, which has also been reported in humans (41).”
BackgroundInteraction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications
Zubirán, R., Cruz‐Bautista, I., & Aguilar-Salinas, C. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01626-2 · Cited by 13
Novel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 14
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0771-8_5 · Cited by 11
Antisense RNA Therapeutics: A Brief Overview
Arechavala‐Gomeza, V., & Garanto, A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2010-6_2 · Cited by 11
Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids
Naber, A., Demus, D., Slieker, R. C., Nicolardi, S., Beulens, J. W. J., Elders, P. J. M., Lieverse, A. G., Sijbrands, E. J. G., Hart, L. M. ‘., Wuhrer, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914844 · Cited by 9
“Moreover, high apo-CIII levels have been linked to insulin resistance and beta-cell destruction [12,13].”
BackgroundBiotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
“Besides, ISIS 304801, now called volanesorsen, was able to reduce apoC-III and TG plasma concentrations in hypertriglyceridemic patients with T2D on top of metformin treatment, together with a marked improvement of glucose disposal and insulin sensitivity [142].”
BackgroundUncovering the role of apolipoprotein C-III in insulin resistance
Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.09.003 · Cited by 9
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
Kosmas, C. E., Sourlas, A., Silverio, D., Montan, P. D., & Guzman, E. (2019) · World Journal of Cardiology · doi:10.4330/wjc.v11.i11.256 · Cited by 8
RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management
Mohammadi, A., Karimian, A., Shokri, K., Mohammadi, A., Karzar, N. H., Bahar, R., Radfar, A., Pakyari, M., & Tehrani, B. N. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10603-4 · Cited by 8
He, D., Fan, Z., Zhang, X., Cao, C., Han, Y. Y., Hu, H., & Zheng, X. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01989-x · Cited by 7
Kim, S. H., Park, W. Y., Kim, B., Kim, J.-H., Song, G., Park, J. Y., Jiao, W., Jung, S. J., Ahn, K. S., Kwak, H. J., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108181 · Cited by 9
Dyslipidemia: Current Perspectives and Implications for Clinical Practice
Majanović, S. K., Cvijanović, O., Detel, D., Jovanović, G. K., Bakula, M., Rahelić, D., Čaljkušić‐Mance, T., Šoić-Vranić, T., & Cvek, S. Z. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98386 · Cited by 13
Targeting triglycerides to lower residual cardiovascular risk
Bubb, K. J., Nelson, A. J., & Nicholls, S. J. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2058489 · Cited by 9
Hypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment
Wieczorek, E., Ćwiklińska, A., & Jankowski, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0189 · Cited by 8
Nucleic acid therapy in pediatric cancer
Li, Y., Huang, B., Xue, Z., Gao, Y., & Zhuo, Z. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106441 · Cited by 8
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 8
Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia
Parthymos, I., Kostapanos, M. S., Liamis, G. L., & Florentin, M. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9020042 · Cited by 6
“Capsules of MAT9001 (1 g four times daily) will be compared with placebo in terms of TG reduction within 12 weeks [38].”
MethodUnanticipated Enhancement of Intestinal TG Output by Apoc3 ASO Inhibition
Syed‐Abdul, M. M., Tian, L., & Lewis, G. F. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319765 · Cited by 4
“23,24,26,28,29,34 What was unexpected was the finding that apoC3 ASO increased lymph triglyceride output.”
Drug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome: Focus on Volnesorsen
Gesner, M., & Frishman, W. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000468 · Cited by 4
“Effects in Diabetes Mellitus A randomized, double-blind, placebo-controlled trial was performed to see how volanesorsen impacts patients with type 2 diabetes mellitus and hypertriglyceridemia.(40) In this study, 15 adult patients with a hemoglobin A 1c greater than 7.”
BackgroundNicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 9
“Similar benefits of apoC3 inhibition on triglyceride levels have been reported [92,94–98].”
BackgroundAntisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials
Ogieuhi, I. J., Callender, K., Odukudu, G.-D. O., Obi, E. S., Muzofa, K., Babalola, A. E., Ugiomoh, O. M.-A., Umenzeakor, K. H., Akingbola, A., Ayoson, C. O., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00682-w · Cited by 5
Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000348 · Cited by 6
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia
ALGhasab, N. S., Fogacci, F., Арманович, А. А., & Cicero, A. F. G. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406270 · Cited by 5
“Digenio A et al. preliminary tested Volanesorsen in a small sample ( N = 15) of patients affected by type 2 diabetes, where impressive reduction in apoC-III (−88%, p = 0.02) and TG (−69%, p = 0.02) levels were associated with a 57% improvement in whole-body insulin sensitivity ( p < 0.001) [84].”
InfluentialBeyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 6
Bozzetto, L., Berntzen, B. J., Kaprio, J. A., Rissanen, A., Taskinen, M., & Pietiläinen, K. H. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.10.005 · Cited by 4
Uncovering the role of apolipoprotein C-III in insulin resistance
Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.04.002 · Cited by 9
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
“(Table 4) Benefits of apo C-III reduction with volanesorsen may extend to T2D patients with moderate HTG (>200 to 500 mg/dL) as it was reported that volanesorsen (300 mg weekly, N = 15) for 15 weeks increased whole body insulin sensitivity by 57%, which in turn significantly lowered plasma glycated albumin and fructos…”
BackgroundNew and Emerging Therapies for Dyslipidemia
Zambon, A., Averna, M. R., D’Erasmo, L., Arca, M., & Catapano, A. L. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.004 · Cited by 5
Investigational therapies for hypercholesterolemia
TOMKIN, G. H., & Owens, D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1315407 · Cited by 6
Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a)
Hanßen, R., & Gouni‐Berthold, I. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0115-0 · Cited by 4
“[60] examined the effects of volanesorsen on triglyceride levels and insulin resistance in a small study (n = 15) of patients with type 2 diabetes (HbA1c > 7.”
BackgroundAlam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02337-1 · Cited by 4
“In addition to TG lowering, volane - sorsen has been shown to reduce apoC-III by ~ 80–88% and increase HDL-C by ~ 42% compared with placebo [ 45–47 ].”
Koška, J., Hu, Y., Furtado, J. D., Billheimer, D. D., Nedelkov, D., Schwenke, D. C., Budoff, M. J., Bertoni, A. G., McClelland, R. L., & Reaven, P. D. (2024) · Diabetes Care · doi:10.2337/dc24-1462 · Cited by 3
Fermented Rice Bran Mitigated the Syndromes of Type 2 Diabetes in KK-Ay Mice Model
Agista, A. Z., Kato, A., Gotō, T., Koseki, T., Oikawa, A., Ohsaki, Y., Yamaki, M., Yeh, C., Yang, S., Ardiansyah, A., et al. (2024) · Metabolites · doi:10.3390/metabo14110614 · Cited by 3
“Type 2 diabetes is often accompanied by abnormalities in lipid metabolism [25].”
Ogunniyi, K. E., Aghasili, C. C., Akinmoju, O. D., Olaiya, V. O., Abib, O. M., Odueke, A., Popoola, H. A., Onyenokwe, V., Onaolapo, D., Usman, A.-A. M., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00762-9 · Cited by 3
“Emerging evidence also suggests potential benefits in improving insulin sensitivity and reducing hepatic steatosis among patients with metabolic syndrome [81].”
Effects of evolving lipid-lowering drugs on carbohydrate metabolism
Tsimihodimos, V., & Elisaf, M. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.012 · Cited by 2
Adeli, K., Xiao, C., Higgins, V., Taher, J., Farr, S., & Lewis, G. F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824048-9.00002-x · Cited by 3
The Influencing Factors of Serum Lipids among Middle-aged Women in Northeast China.
Zhang, X., Shen, L., Wang, Y., Guo, X., Dou, J., Lv, Y., Xue, Z., Zhang, A., Jin, L., & Yao, Y. (2018) · PubMed Central · Cited by 2
Elbahloul, M. A., Gamal, A., Maihoub, O., Elbaz Hassan, M. M., Attia, M. K., Salah, A. M., Elboraay, T., Awad, A. K., Akoum, A., Elazab, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70717 · Cited by 1
Kumar, A., Lakhawat, S. S., Malik, N. K., Sharma, V., Singh, Y., Jain, A., Sharma, V., Singh, S. K., & Sharma, P. K. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110500 · Cited by 1
ApoC3 Attenuates Platelet Activation Through GPIIb/IIIa Receptor Interaction
Holzer, M., Gruden, E., Ćurčić, S., Cvirn, G., & Marsche, G. (2025) · Cells · doi:10.3390/cells14181411 · Cited by 1
“Volanesorsen, tested in patients with hypertriglyceridemia and type 2 diabetes, achieved even greater reductions of up to 88% [27].”
Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes
Pirillo, A., Norata, G. D., & Catapano, A. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_7 · Cited by 3
Atherosclerosis is the outcome of adaptive complexity in the Arterial Endothelial Microenvironment
Roy, T., Ray, A. G., & Bandyopadhyay, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00081-5 · Cited by 1
High-density lipoprotein (HDL) as an indicator for alcohol use in a psychiatrically ill population
Benson, N. M., Yakubu, A., Ren, B., Aboud, C., Vargas, V., Greenfield, S. F., & Busch, A. B. (2024) · Alcohol and Alcoholism · doi:10.1093/alcalc/agae028 · Cited by 2
Síndrome de Quilomicronemia Familiar: Algoritmo Diagnóstico
Colaco, I. B., Araújo, F., Aguiar, P., Cruz, D., Bourbon, M., Duarte, J. S., & Veríssimo, M. T. (2021) · Medicina Interna · doi:10.24950/rspmi.r.92.4.2021 · Cited by 1
Pathogenese und Bedeutung der diabetischen Dyslipidämie
Parhofer, K. G., & Li-ya, W. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0413-0
Antisense Technology: Liver Targeting and Beyond for Drug Discovery
Geary, R. S., Baker, B. F., & Monia, B. P. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015714-00062 · Cited by 1
Self-citationBrunzell, J. D., & Failor, R. A. (2018) · DeckerMed Medicine · doi:10.2310/fm.1569
Hussain, A., & Ballantyne, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00028-5
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Bobik, A., Cohen, N. D., Jenkins, A. J., Kyaw, T. S., SULLIVAN, D. R., Wu, X., Yu, X.-Y., & Little, P. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_30
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_8
Zachariah, G. A. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.11.004 · Cited by 12
Sobral, M. V. S., Queiroz, I., dos Santos, J. P. P., Pirolla, R. D. C., Martins, D. C., Silva, G., da Silva, D. P., Assakawa, C., Vilela, T. A. A., Filho, M. A. G., et al. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001875
Outland, E. H., Xin, Y., Dickson, A. L., Mundo, S., Tao, R., Zhong, X. Y., Karakoc, G., Serley, S., Jiang, L., Cox, N. J., et al. (2025) · medRxiv · doi:10.1101/2025.03.07.25323588 · Cited by 1
Masood, A., Qureshi, A. U. H., Khalid, Z., Shahid, H., Malik, A. R. K., Javed, S., Mandahar, M., Amanullah, A., Siddiqui, Y., Anwar, T., et al. (2026) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2026.3543
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
“In the corresponding phase 2 trials of individuals with mild-to-moderate hypertriglyceridemia (a), apoCIII inhibitors lowered remnant cholesterol levels 48% for plozasiran, 54% for olezarsen, and 59% for volanesorsen (Figure 5, red bars) [28,102,103,106].”
Apolipoprotéine C3 : élément essentiel du métabolisme lipidique et nouvelle cible thérapeutique
Akkoura, L., & Vergès, B. L. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.009
Olezarsen for Hypertriglyceridemia: A New Therapy Update with Systematic Review and Meta-Analysis
Khan, N., Shahid, H., Choudhry, H. H. A., Irshad, M., Shaikh, H. A., Shahid, S., Afridi, F. N., Mian, S. M., Mateen, L., Khan, H., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001341
Damianaki, A., Stambolliu, E., Iliakis, P., Theofilis, P., Vakka, A., Kalliakouda, E., Patsalis, P., Konstantinidis, D., & Petras, D. I. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07934-y
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_5
Apolipoprotein CIII as a therapeutic target in obesity-associated metabolic dysfunction
Valladolid‐Acebes, I., Berggren, P., & Juntti‐Berggren, L. (2026) · Advances in Biological Regulation · doi:10.1016/j.jbior.2026.101183
Metadata
- Authors
- Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., Baker, B. F., Bhanot, S., & Crooke, R. M.
- Affiliations
- Akcea Therapeutics, Cambridge, MA
- University of Pennsylvania (US)
- Ionis Pharmaceuticals (United States) (US)
- Profil Institute for Clinical Research (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-06
- Volume
- 39
- Issue
- 8
- Pages
- 1408-1415
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2418001336
- Cited by
- 170
- References
- 41
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 16 · 2023: 16 · 2022: 18 · 2021: 18 · 2020: 19 · 2019: 23 · 2018: 13 · 2017: 14 · 2016: 7
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- volanesorsen, apolipoprotein C-III, antisense oligonucleotides, type 2 diabetes, hypertriglyceridemia, insulin sensitivity, insulin resistance, triglycerides, HDL cholesterol, glycated albumin, fructosamine, glycemic control, glucose disposal
- MeSH terms
- Aged, Anticholesteremic Agents, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Hypertriglyceridemia, Biomarkers, Oligonucleotides, Antisense, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.